On Dec. 23, 2003, the USDA announced the first case of mad cow disease in the United States, and a Washington dairy cow upended the global beef trade Two days before Christmas, one Holstein cow turned a quiet holiday week into a test of American food safety and trade. Dec. 23, 2003, was supposed to be a slow news day before the holidays. Instead, Agriculture Secretary Ann Veneman stepped to a podium in Washington, D.C., with news officials had long insisted was unlikely: a dairy cow in Washington state had tested positive for bovine spongiform encephalopathy, better known as mad cow disease. It was the first confirmed case on American soil. One Cow, Many Borders   The animal was a Holstein dairy cow that had been slaughtered earlier that month at a plant in Washington state. It had been unable to walk, which is why it was sampled for testing, and a USDA lab in Ames, Iowa, flagged the result. Veneman told reporters that the meat from the cow had gone into the food supply, but that the brain, spinal cord and other tissues associated with the disease had been removed. Officials stressed that the risk to consumers was extremely low. The disease had been tied in Britain to a fatal human illness, variant Creutzfeldt-Jakob disease, which gave the announcement a weight far beyond a single farm. American officials had spent years describing the country's safeguards as strong, and for a few hours before Christmas, that claim was put to its first real public test. The cow, it turned out, had been sampled precisely because the system was designed to look for it. The economic shock came fast. Within days, more than 30 countries restricted imports of American beef, including Japan and South Korea, two of the industry's most valuable customers, in a trade worth roughly $3 billion a year. Investigators later traced the cow to Canada, which reframed the story as a North American problem rather than a purely domestic one. The USDA soon announced new safeguards, including a ban on using so-called downer cattle for human food, a rule that would have kept this very cow out of the supply. The episode ended with an odd kind of reassurance: the nation's first case arrived on the same day it was caught, and a Christmas week scare produced the tightening of rules that had, until then, been declared sufficient.  

On December 11, 2020, the FDA Authorized the First COVID-19 Vaccine for Emergency Use in the United States Less than a year after the virus was first identified, a late-Friday regulatory decision opened the door to the biggest vaccination effort the country had ever attempted. On Friday, Dec. 11, 2020, the U.S. Food and Drug Administration issued an emergency use authorization for the vaccine developed by Pfizer and BioNTech, making it the first COVID-19 vaccine cleared for use in the United States. The decision came on a winter evening when the country was recording some of its highest daily death tolls of the pandemic. The Green Light   The authorization followed a meeting of the FDA's outside advisory committee the previous day, where independent experts voted 17 to 4, with one abstention, to back the vaccine for people 16 and older. The agency's review rested on a large clinical trial that found the two-dose regimen to be about 95 percent effective at preventing symptomatic COVID-19. Acting Commissioner Stephen Hahn signed off, and the agency described the action as the first emergency use authorization of a COVID-19 vaccine. The vaccine, made with messenger RNA technology that had never before been used in an approved vaccine, had moved from genetic sequence to regulatory clearance at a pace without precedent. Earlier vaccines had typically taken a decade or more to develop. The shots still needed to travel, however, and they had to be kept at ultra-cold temperatures, a logistical puzzle that required specialized freezers and carefully planned shipping long before the paperwork was complete. Distribution began almost immediately. Shipments left Pfizer's Kalamazoo, Michigan, facility over the weekend, and the first vaccinations in the United States were administered on Monday, Dec. 14, to health care workers. Within days, the agency's attention turned to a second candidate from Moderna, which received its own authorization on Dec. 18. The speed of the effort drew scrutiny as well as celebration, with regulators and public health officials stressing that the review had not skipped its safety steps. For a country that had spent months waiting for any sign of an exit, the announcement was a quiet piece of paper with enormous consequences. Yet the authorization was only the beginning of a long campaign, since the hardest part, persuading hundreds of millions of people to roll up their sleeves, still lay ahead.  

On Dec. 8, 2020, a 90-year-old grandmother in Coventry rolled up her sleeve and became the first person in the world to receive a fully tested COVID-19 vaccine outside a clinical trial Britain called it V-Day, and its first patient was a retired jewelry shop assistant who was a week shy of her 91st birthday. The first dose of the Pfizer-BioNTech vaccine given outside a trial went into the arm of Margaret Keenan at University Hospital in Coventry, England, on the morning of Dec. 8, 2020. The jab came less than a year after the virus had first been identified, and days after British regulators authorized the shot. The National Health Service had spent weeks preparing for the moment, and it arrived with cameras waiting. V-Day in Coventry   Keenan, a former jewelry shop assistant, was among the first patients in line as the NHS began its mass vaccination program at hospital hubs across the United Kingdom. Nurse May Parsons administered the injection, and the moment was broadcast around the world. Britain had become the first Western country to authorize a fully tested COVID-19 vaccine, and it moved quickly to put doses into patients, prioritizing older adults and care home residents, who were the most vulnerable to the disease. Keenan, who was just a week away from turning 91, was among the first to be called. After the shot, she described it as the best early birthday present she could have wished for, a line that was quoted in headlines around the world. For a pandemic that had kept families apart for most of a year, one small needle stick in a Midlands hospital carried more weight than its few seconds suggested. The second person vaccinated that day was William Shakespeare, an 81-year-old from Warwickshire, a coincidence of names that British newspapers could scarcely resist. Within hours, the story had shifted from a scientific milestone into something close to a national ritual, with hospitals sharing images of the first patients and health officials urging the public to keep following restrictions while the rollout began. The shots themselves required two doses and carefully controlled ultra-cold storage, a logistical challenge that had dominated planning for weeks. Yet the images that endured were not of freezers or spreadsheets. They were of an older woman in a hospital gown and a patterned T-shirt, smiling beneath a mask, at the start of the long task of ending a global emergency.  

Dec. 3, 2018: Japan's Hayabusa2 Probe Takes Its Place Beside the Asteroid Ryugu to Begin a Hunt for Buried Secrets of the Solar System After more than three years of travel, a small Japanese spacecraft arrived at a rubble-pile asteroid to ask where Earth's water and organic ingredients came from. On Dec. 3, 2018, the Japan Aerospace Exploration Agency's Hayabusa2 spacecraft was in position at the asteroid Ryugu, a dark, spinning object roughly half a mile wide that orbits the Sun far from any ordinary neighborhood. It had launched in December 2014. The goal was to touch the surface, collect material, and bring it home. The Rendezvous   Hayabusa2 was the successor to the original Hayabusa, which returned a tiny amount of dust from the asteroid Itokawa in 2010 after a famously troubled journey. This time JAXA aimed at a carbon-rich asteroid, a type thought to preserve material from the early solar system, including possible clues about water and organic compounds. The spacecraft had reached Ryugu's vicinity in June 2018, using ion engines to match the asteroid's path and to hover at a distance of about twelve miles. In the months that followed, its cameras revealed a surface far rockier than scientists had expected, strewn with boulders and lacking the smooth, sandy patches mission planners had hoped might make a safe landing zone. Controllers would have to rethink their choices. The mission team had picked a target the shape of a spinning top, then found it covered in obstacles. The work of the following year went on to include small hopping rovers released onto the surface, a copper impactor that blasted an artificial crater, and two touchdowns to gather samples, including material from beneath the surface. Hayabusa2 left Ryugu in November 2019 and in December 2020 dropped a capsule over the Australian outback. The capsule held about 5.4 grams of dark grains, far more than the mission's target of 0.1 gram. Analysis later found organic molecules and amino acids in the samples. A probe built to fetch a pinch of dust returned with a heavy payload, from a rock that had spent billions of years drifting through the dark.  

Dec. 2, 2020: The United Kingdom Becomes the First Western Nation to Authorize a COVID-19 Vaccine With a regulatory green light for the Pfizer-BioNTech shot, Britain turned a year of lockdowns and loss toward a new kind of waiting: the wait for a needle. On Dec. 2, 2020, the UK's medicines regulator, the MHRA, granted temporary authorization to the vaccine developed by Pfizer and BioNTech. It was the first time a Western country had approved a fully tested COVID-19 vaccine for public use, and it came barely eleven months after the virus first appeared in the news. The Green Light   The decision followed a rolling review of data from the companies' large Phase 3 trial, which had reported roughly 95 percent efficacy against symptomatic COVID-19. The regulator's approval allowed the shot to be supplied under temporary authorization, and Prime Minister Boris Johnson announced the news on social media, calling it incredible. The vaccine was built on messenger RNA, a technology that had never before been used in an approved vaccine for the public. Researchers had spent years refining it in relative obscurity, and now it had gone from laboratory promise to government approval in a stretch of months that vaccine specialists once would have considered impossible. The approval also set off an unusual bit of international jostling. Other countries, whose regulators were still deep in their own reviews, now had to explain why a rival had reached the finish line first. For a pandemic that had made borders, schedules and ordinary life feel unmovable, the speed of the paperwork was, in its own way, a small shock. The first people in Britain to be vaccinated would not have to wait long. On Dec. 8, Margaret Keenan, a 90-year-old woman in Coventry, became the first person in the world to receive the Pfizer-BioNTech shot outside a clinical trial, in a hospital that had been turned into one of the country's first vaccination hubs. The U.S. Food and Drug Administration followed with its own emergency use authorization on Dec. 11, and other nations soon joined in. The approval did not end the pandemic; cases and deaths kept climbing through the winter, and supplies were limited at first. But it changed the shape of the story. After months in which the most hopeful news was a downward curve on a chart, the headline now involved something people could actually roll up a sleeve for. The most anticipated science of the year arrived not with fanfare, but with a regulatory notice.  

On Nov. 28, 2018, a Chinese scientist walked onto a Hong Kong stage to defend the birth of the world's first gene-edited babies He Jiankui's public account of the CRISPR twins drew gasps, condemnation and a reckoning over who gets to rewrite the human genome. Scientific revolutions usually arrive in peer-reviewed journals. This one arrived in the news first. By Nov. 28, 2018, reports had already claimed that a researcher in Shenzhen had edited the DNA of human embryos and that two girls had been born from them. That afternoon, the man behind the claim had to explain himself to a roomful of his peers. The Hong Kong Stage   The venue was the Second International Summit on Human Genome Editing at the University of Hong Kong, where He Jiankui, then an associate professor at the Southern University of Science and Technology in Shenzhen, was scheduled to speak. He told the audience that he had used the CRISPR tool to alter a gene called CCR5 in embryos, with the aim of making children resistant to HIV infection. He said the work had produced twin girls, known publicly by the pseudonyms Lulu and Nana, and that a second pregnancy might also be underway. The claim had not been published or independently verified. His university said he had been on unpaid leave since February 2018 and that it had not known about the project. Many scientists in the room had spent years debating whether such an experiment should ever be attempted. They were now hearing that someone had already done it, and that the news had broken before any journal had a chance to weigh in. The reaction was swift. The summit's organizing committee said the next day that the work was irresponsible and failed to conform to international norms, and criticized the lack of transparency around it. Researchers pointed out that the embryos were healthy and that proven ways to protect children from HIV already existed. Chinese authorities opened an investigation, and in December 2019 a court in Shenzhen sentenced He to three years in prison and fined him three million yuan. The technology he used had been celebrated for its precision, but the episode showed that the harder problem was never the cutting. It was deciding, in advance and in public, who gets to hold the scissors.  

On Nov. 26, 2011, NASA Launched a Car-Sized Rover Called Curiosity Toward Mars on a Mission Meant to Last Two Years A one-ton robot left Florida on an Atlas V rocket with a simple question: could Mars ever have supported life? The morning after Thanksgiving weekend began, an Atlas V rocket stood on Space Launch Complex 41 at Cape Canaveral, Florida. On Nov. 26, 2011, it lifted off carrying NASA's Mars Science Laboratory, a spacecraft built around a rover the size of a small car. The rover had been named Curiosity by a sixth-grade student, Clara Ma, in a national student contest. Its destination was 354 million miles away. The Long Cruise   The Atlas V launched at 10:02 a.m. Eastern time and sent the spacecraft on a roughly eight-month cruise to Mars. Curiosity was far larger than the rovers that came before it. It weighed about 900 kilograms, or nearly a ton, and carried ten science instruments, including a laser that could vaporize rock from a distance and a chemistry lab built to analyze soil and powdered stone. NASA put the mission's cost at about $2.5 billion. Its goal was less to find life than to find out whether Mars ever offered the conditions for it. The rover was bound for Gale Crater, where a mountain of layered rock rose from the crater floor like a geological history book. Engineers had picked it partly because the layers promised a record of how the planet changed over time. Getting there, however, required a landing method nobody had tried: the rover would be lowered to the surface on cables from a hovering rocket-powered platform. The launch was the easy part, and everyone involved knew it. The gamble paid off on Aug. 6, 2012, UTC, when Curiosity touched down inside Gale Crater after the so-called seven minutes of terror, the descent that had to be completed without any help from Earth. Within months, it found evidence of an ancient streambed, and later analysis of mudstone showed that the crater once held a lake with chemistry that could have supported microbial life. The prime mission was set at one Martian year, about 687 Earth days. Curiosity passed that mark long ago and was still climbing Mount Sharp more than a decade later, working through terrain no engineer had seen when the rocket left the pad. A rover that left Earth to answer one question has spent years producing new ones, which is how a two-year plan turned into a career.  

On Nov. 21, 2006, Seven Governments Gathered in Paris and Signed an Agreement to Build a Miniature Sun The ITER pact joined rivals and allies in one of the most ambitious science projects ever attempted: a machine meant to prove fusion power can work. Treaty signings are usually about borders, trade or weapons. On Nov. 21, 2006, in the Élysée Palace in Paris, the signatures went onto something stranger: a joint agreement to build an experimental reactor meant to mimic the process that powers the Sun. The European Union, the United States, Russia, Japan, China, India and South Korea put their names to the ITER agreement, committing to a shared machine that none of them wanted to build alone. A Star in France   The idea behind ITER is simple to state and brutally hard to achieve. Fusion joins light atomic nuclei and releases energy, but only when fuel is heated to extreme temperatures and held in place long enough for the reaction to sustain itself. ITER's design, a doughnut-shaped tokamak that uses powerful magnets to confine superheated plasma, aims to produce roughly ten times the thermal power it takes to heat the fuel. The goal was never to put electricity on the grid. It was to demonstrate that the physics scales up. The site had been settled the year before: Cadarache, in southern France, won out over a rival bid from Japan after a long diplomatic contest. The 2006 signing turned that compromise into a legal framework, with each partner agreeing to contribute components and funding. The partners had spent years haggling over who would host the machine, and now they had to agree on who would pay for it. The agreement created a new international organization to oversee construction, and its design relied on an unusual arrangement: most contributions would arrive as finished hardware rather than cash, with parts built in factories across several continents and shipped to France. That structure kept every government invested in the outcome, but it also made coordination a constant challenge. Schedules slipped and cost estimates grew in the years that followed, and the first-plasma date announced around the time of the signing was later pushed back repeatedly. Still, the partners kept building. A project conceived partly as a Cold War-era gesture of scientific cooperation outlasted the political tensions that have strained relations among its members since. The machine meant to hold a star has proven slower to assemble than the diplomacy that launched it, and in some ways more stubborn.  

On Nov. 18, 2013, NASA's MAVEN Spacecraft Rocketed Toward Mars to Solve the Mystery of the Vanishing Atmosphere A single Atlas V launch from Florida set out to answer how a planet that once may have had rivers and lakes ended up cold, dry and nearly airless. On the afternoon of Nov. 18, 2013, an Atlas V rocket climbed off the pad at Cape Canaveral Air Force Station in Florida carrying a spacecraft with an unusual assignment. Most Mars missions had gone to look at the ground. MAVEN, short for Mars Atmosphere and Volatile EvolutioN, was built to look up, at the thin, tattered air that is all that remains of whatever Mars once had. The Missing Sky   Orbiters and rovers had already turned up channels, minerals and ancient lakebeds that pointed to a wetter, warmer Mars in the distant past. Water that flows on the surface needs a thicker atmosphere than the one the planet has now, so the obvious question was where that atmosphere went. MAVEN was NASA's attempt to measure the answer rather than guess at it. The spacecraft lifted off at 1:28 p.m. Eastern time aboard an Atlas V 401, on the first day of its launch period. Its plan was to settle into a looping orbit around Mars and sample the planet's upper atmosphere directly, while tracking the solar wind and ultraviolet light that strip gas away into space. Its instruments were designed to watch that process in action instead of inferring it from rocks. It was a small, focused mission built around a single big question, and its mission team knew that the answer might reveal as much about Earth's own long-term fate as about its neighbor's. It would be a ten-month trip before anyone could begin to find out. The trip ended on Sept. 21, 2014, when MAVEN fired its engines and slipped into orbit around Mars. It arrived just three days before India's Mars Orbiter Mission, which had left Earth two weeks before MAVEN, on Nov. 5, 2013. The two missions had set out in the same narrow launch window and finished the journey nearly together. Once MAVEN began its science work, it confirmed that the solar wind was a major force in eroding the Martian atmosphere, and NASA reported in 2015 that the loss was far greater during solar storms. The spacecraft that was built to look at what Mars had lost became, in effect, a witness to the loss still happening. Mars is not simply a planet that once had air. It is a planet whose air is, even now, still leaving.  

Nov. 16, 2020: Moderna Announces That Its mRNA COVID-19 Vaccine Was 94.5% Effective in Its Phase 3 Trial A Monday-morning press release put a number on the hope that a new kind of vaccine could end the worst pandemic in a century. On Monday, Nov. 16, 2020, a Cambridge, Massachusetts, biotech company that had never brought a product to market announced results that would change the pandemic's trajectory. Moderna said an early look at its Phase 3 trial showed its COVID-19 vaccine candidate, mRNA-1273, was 94.5% effective at preventing symptomatic disease. The figure arrived as case counts climbed across the United States and Europe. The Interim Analysis   The trial, run with the National Institutes of Health, had enrolled about 30,000 volunteers across the United States. An independent data safety monitoring board conducted the first interim analysis once 95 participants had developed confirmed symptomatic COVID-19. Of those cases, 90 were in the placebo group and only five were in the group that received the vaccine. The board also counted 11 severe cases, and all 11 were in the placebo group. Moderna said the vaccine could be stored at standard refrigerator temperatures, 36 to 46 degrees Fahrenheit, for 30 days, and at minus 4 degrees for six months, a practical edge for distribution. The company's design work had begun in January 2020, shortly after the virus's genetic sequence was published. A technology long considered promising but unproven had gone from a computer file to a late-stage trial in under a year, which is a pace that vaccine development had never come close to matching. The announcement came one week after Pfizer and BioNTech had reported that their own mRNA vaccine was more than 90% effective, so Moderna's result served as confirmation as much as surprise. Two different companies, using the same underlying idea, had arrived at results far above the 50% efficacy that regulators had set as a minimum bar. Moderna cautioned that the data were preliminary and still needed review by regulators. That review came quickly. The U.S. Food and Drug Administration granted emergency use authorization to the vaccine on Dec. 18, 2020. For a company that had spent a decade as a scientific curiosity, a single Monday press release had been enough to turn years of skepticism about messenger RNA into one of the most closely watched medical results of the century.  

Nov. 13, 2014: The Day After a Comet Landing, Philae's Race Against a Dying Battery Begins A day after a bouncing touchdown on Comet 67P, the little lander in a shadowed spot had hours to do its science. Landing on a comet was the easy headline. By Nov. 13, 2014, the European Space Agency's Philae lander sat tilted somewhere on Comet 67P/Churyumov-Gerasimenko, far from its intended site, and the mission team in Darmstadt, Germany was racing to get as much science out of it as possible. Borrowed Time   Philae had touched down on Nov. 12 after a ten-year ride aboard the Rosetta spacecraft. The harpoons meant to anchor it to the surface did not fire, and the lander bounced before settling in a spot partly shadowed by a cliff or crater wall. That left its solar panels with far less sunlight than planned. The mission's backup plan was simple: use the primary battery to complete as many experiments as possible before it ran out. Controllers sequenced the instruments in order of priority, and Philae returned its first-ever data from a comet's surface, including measurements from instruments built to analyze the surface and the comet's makeup. The comet was not a quiet place to work. Every command had to fit into windows when Rosetta was overhead to relay the signal. The lander's fate was written in its orbit, in a way, by geometry and light rather than by anything the team could adjust. As the battery ran low, the team made a last-ditch attempt to shift the lander's position, hoping to catch more sunlight. Philae then went silent as its power ran out, entering a kind of hibernation. The mission had delivered the first sampling and surface analysis attempts ever made on a comet. Then, in June 2015, the lander briefly woke and phoned home as the comet neared the Sun, before falling quiet again for good. Its resting place was only pinpointed in 2016, when Rosetta photographed it wedged in a dark crevice. A machine designed to anchor itself had spent its brief life unanchored, and its best discoveries came from the shadows it never meant to land in.  

On October 29, 2004, NASA's Cassini Spacecraft Made Its First Close Flyby of Saturn's Mysterious Moon Titan Peering beneath an orange haze that had hidden a world for centuries, Cassini revealed a landscape unlike anything else in the solar system. On October 29, 2004, the Cassini spacecraft swept to within about 745 miles of Titan, Saturn's largest moon, in the first of dozens of close encounters that would define its 13-year mission. For decades, Titan's thick nitrogen-methane atmosphere had hidden its surface from every telescope and passing probe, turning the moon into one of the solar system's great blank spots. Cassini's instruments, built to pierce that orange shroud, were about to change that. Behind the Haze   Cassini's radar and imaging instruments cut through Titan's dense atmosphere in ways visible light cameras never could, returning the sharpest views of the moon's surface humanity had ever seen. Scientists spotted bright and dark regions suggesting complex geology, along with hints of the methane lakes and dune fields that later missions would confirm in detail. Mission scientists at NASA's Jet Propulsion Laboratory described the data as immediately reshaping assumptions about Titan's surface, which some had expected to be smooth or ocean-covered. Instead, the flyby revealed a moon carved by processes eerily similar to Earth's own, just built from entirely different chemistry. It was a reminder that familiar shapes don't require familiar materials. The October 29 pass was a prelude to Cassini's most dramatic achievement regarding Titan: the release of the European Space Agency's Huygens probe, which would land on the moon's surface just months later in January 2005. That descent, made possible by the orbital groundwork laid during early flybys like this one, delivered the first images ever taken from the surface of a world in the outer solar system. Cassini would go on to make more than 120 targeted Titan flybys before its mission ended with a deliberate plunge into Saturn in 2017. The moon it helped reveal, with its rivers and seas of liquid methane, remains one of the strongest candidates for exotic life beyond Earth, a possibility this single flyby helped bring into focus.  

On October 23, 2001, Steve Jobs Introduced the World to the iPod A small white device with a click wheel promised to put a thousand songs in your pocket—and quietly began rewriting the rules of the music business. On October 23, 2001, in a modest auditorium at Apple's Cupertino headquarters, Steve Jobs pulled a small white rectangle from his pocket and told the assembled press that Apple was introducing a breakthrough digital device. The company was still years from the iPhone, still recovering from the dot-com bust, and best known for candy-colored iMacs. What Jobs held up that day looked unassuming, almost toy-like, but it carried a claim that sounded almost absurd for its time. 1,000 Songs   The device was the iPod, a 6.5-ounce gadget with a 5GB hard drive that Apple promised could hold "1,000 songs in your pocket." It used a mechanical scroll wheel for navigation, connected via FireWire for what was then blazing-fast transfers, and carried a price tag of $399 — steep enough that some technology writers dismissed it as a niche product for Mac loyalists. Compared to the clunky MP3 players already on the market, most of which held a fraction of the songs and ran on double-A batteries, the iPod felt like it had arrived from another decade entirely. Jobs, dressed in his familiar black turtleneck, framed it not as a gadget but as a lifestyle shift, a way of carrying an entire music collection without carrying anything heavy at all. Skeptics wondered aloud whether Apple, a computer company, had any business making a music player — a question that would soon answer itself in the most emphatic terms possible. The first iPod shipped a few weeks later, compatible only with Macs, which limited its reach in a market still dominated by Windows PCs. But the device's design language — minimalist, white, built around Apple's new iTunes software — set a template the company would refine for years. Within two years, Windows compatibility and the iTunes Music Store would turn the iPod into a cultural fixture, its white earbuds becoming a visible symbol of the early 2000s. The record labels that once shrugged off digital music would soon find themselves negotiating with the company that had made downloading songs feel effortless, a shift that began with one modest press event and a device nobody outside Cupertino was sure the world actually needed.  

On October 22, 2008, the T-Mobile G1 Went on Sale, Introducing the World to Android A slide-out keyboard and a search-engine giant's operating system quietly launched the smartphone war's second act. On October 22, 2008, shoppers filing into T-Mobile stores across the United States could walk out with a chunky, slide-out-keyboard handset called the G1 — the first phone ever to run Google's new Android operating system. Built by HTC and priced at $179 with a two-year contract, it arrived just over a year after Apple's iPhone had redefined what a phone could be, and few outside the tech press understood they were watching the opening move of a rivalry that would reshape the entire industry. The Underdog Debut   The G1 was, by most measures, an awkward machine. It had a trackball, a physical keyboard that popped out from beneath the screen, and no multi-touch pinch-to-zoom, a deliberate step around Apple's patents. Reviewers at the time noted its clunky software and middling battery life, and Google itself was cautious about the launch, treating Android less as a finished product than as an open invitation to manufacturers and developers who felt boxed out of Apple's tightly controlled ecosystem. T-Mobile sold out its initial stock within days, driven less by the hardware than by curiosity about what Google intended to build. What followed was not immediate dominance but a slow accumulation of scale. Android's open-source licensing meant that Samsung, Motorola, LG, and eventually manufacturers worldwide could adopt it for free, and within three years Android phones outsold iPhones globally. The G1 itself was discontinued within two years, a footnote next to the operating system it introduced, which today runs on the majority of smartphones on Earth — proof that the clumsiest first draft can still write the ending.  

On October 18, 2019, Christina Koch and Jessica Meir Stepped Into History Outside the ISS A scheduling quirk months earlier had delayed this moment, but on this day two women finally floated alone into the vacuum of space together. On October 18, 2019, NASA astronauts Christina Koch and Jessica Meir opened the hatch of the International Space Station and drifted out into open space, becoming the first all-female team to conduct a spacewalk in the six-decade history of extravehicular activity. Their task was technical — replacing a failed power controller — but the moment carried a weight far beyond hardware. The Long Way Up   The spacewalk almost happened months earlier, in March 2019, when Koch and fellow astronaut Anne McClain were slated to go out together. NASA scrubbed that plan after discovering there weren't enough medium-sized spacesuit torsos aboard the station to fit both women, a logistical gap that drew sharp public criticism about how spaceflight infrastructure had been designed. Koch went out instead with a male colleague, and the milestone waited. By October, the suit situation was resolved, and Meir, on her first spaceflight, joined Koch for a seven-hour, seventeen-minute excursion. They successfully swapped the faulty battery charge-discharge unit, restoring full power capacity to the station's solar array circuit. The fix worked precisely as engineers had hoped, a quietly competent end to a walk that the whole world had been watching for reasons that had nothing to do with batteries. Inside the station, NASA astronaut Jessica Meir spoke with President Donald Trump and NASA administrator Jim Bridenstine during the walk, fielding a call that framed the moment as a national milestone rather than a routine repair. Koch would go on to spend 328 days in space, setting a record for the longest single spaceflight by a woman, while Meir's own path back to Earth carried the quiet distinction of having been part of the first spacewalk performed entirely by women. NASA had conducted more than 200 spacewalks since 1965 before this one finally matched its astronaut corps to its long-overdue moment, a gap closed not by grand ceremony but by two women fixing a battery a few hundred miles above the planet that had kept them waiting.